|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It
2
FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer
3
Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301
4
FDA Sends CRL to Cingulate for CTx-1301
5